At ADLM 2024 (formerly the AACC Annual Scientific Meeting Clinical Lab Expo) in Chicago , more than 300 experts will present cutting-edge research and technology that will shape the future of laboratory medicine and improve patient care. From July 28-August 1 , the meetings 250-plus sessions will delve into a variety of timely topics, including the health consequences of ending federal protection for abortion in the U.S., a recent Food and Drug Administration (FDA) ruling that could significantly impede patient access to essential laboratory developed tests, and how to harness data science to achieve health equity.
The case for clinical trials of lab tests. Clinical trials are the recognized standard for evaluating pharmaceuticals and other clinical interventions. In the meetings opening plenary, Dr. Patrick M. Bossuyt will make a compelling, research-based argument for why clinical trials of laboratory tests should also be used to support practice guidelines, reimbursement decisions, and more. Dr. Bossuyt is the recipient of the 2024 Wallace H. Coulter Lectureship Award and a professor of clinical epidemiology at the University of Amsterdam .
Lymphoma biomarkers and therapeutic targets from mass spectrometry-driven proteomics. Dr. Kojo S.J. Elenitoba-Johnson, chair of the department of pathology and laboratory medicine at Memorial Sloan Kettering Cancer Center, will deliver a plenary about the emergence of mass spectrometry as a way to assess complex protein mixtures in patient tissue samples, a technique that allows clinicians to detect cancer and develop more targeted treatments.
Pharmacogenetic testing in precision health. In this plenary, Dr. Ron H.N. van Schaik , professor of pharmacogenetics at Erasmus University Medical Center, will explain how pharmacogenetics uses peoples unique genetic profiles to develop personalized therapies for diseases. Hell describe recent challenges and successes in this field that could benefit patients in psychiatry, cardiology, and oncology, along with pharmacogenetic-testing developments that will further refine treatments.
Providing more options in HIV prevention. Current HIV-prevention medications have limitations. Oral antiretrovirals combining tenofovir and emtricitabine reduce HIV only in certain people, while an injectable form of cabotegravir is effective but expensive. In this plenary, Dr. Sharon L. Hillier , director of reproductive infectious disease research at Magee-Womens Research Institute, will discuss the development of new prevention options for at-risk populations.
